These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18835010)

  • 41. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Novel anticoagulants for stroke prevention in atrial fibrillation].
    Baumhäkel M; Schirmer SH; Böhm M
    Dtsch Med Wochenschr; 2010 Nov; 135(46):2304-8. PubMed ID: 21064013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New anticoagulants in the prevention and treatment of venous thromboembolism].
    Keltai M; Keltai K
    Orv Hetil; 2011 Jun; 152(25):983-92. PubMed ID: 21642050
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
    Wong PC; Crain EJ; Watson CA; Xin B
    J Thromb Haemost; 2009 Aug; 7(8):1313-20. PubMed ID: 19500242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Turpie AG; Kreutz R; Llau J; Norrving B; Haas S
    Thromb Haemost; 2012 Nov; 108(5):876-86. PubMed ID: 23014816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [New oral anticoagulants for atrial fibrillation: a neurologist's view].
    van Dijk EJ; Koudstaal PJ; Roos YB; Brouwers PJ; Kappelle LJ
    Ned Tijdschr Geneeskd; 2012; 156(39):A5283. PubMed ID: 23009824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New anticoagulants for atrial fibrillation.
    Sobieraj-Teague M; O'Donnell M; Eikelboom J
    Semin Thromb Hemost; 2009 Jul; 35(5):515-24. PubMed ID: 19739042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
    Kar S; Bhatt DL
    Coron Artery Dis; 2012 Sep; 23(6):380-90. PubMed ID: 22728913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.
    Merli G; Spyropoulos AC; Caprini JA
    Ann Surg; 2009 Aug; 250(2):219-28. PubMed ID: 19638915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New oral anticoagulants in the ED setting: a review.
    Pollack CV
    Am J Emerg Med; 2012 Nov; 30(9):2046-54. PubMed ID: 22795419
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
    Schellong S
    Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential of new anticoagulants in patients with cancer.
    Weitz JI
    Thromb Res; 2010 Apr; 125 Suppl 2():S30-5. PubMed ID: 20434001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New oral anticoagulant drugs in cardiovascular disease.
    Ahrens I; Lip GY; Peter K
    Thromb Haemost; 2010 Jul; 104(1):49-60. PubMed ID: 20539909
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New anticoagulants for the treatment of venous thromboembolism.
    Prandoni P; Dalla Valle F; Piovella C; Tormene D; Pesavento R
    Minerva Med; 2013 Apr; 104(2):131-39. PubMed ID: 23514989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
    Tripodi A; Palareti G
    J Intern Med; 2012 Jun; 271(6):554-65. PubMed ID: 22443239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The current and future role of the novel oral anticoagulants--indications beyond atrial fibrillation.
    Lee A; Rajaratnam R
    Heart Lung Circ; 2014 Jan; 23(1):2-9. PubMed ID: 24183214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rivaroxaban for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Fundam Clin Pharmacol; 2012 Feb; 26(1):33-8. PubMed ID: 21851388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.